Integrated Stress Response Activity Marks Stem Cells in Normal Hematopoiesis and Leukemia

van Galen, Peter; Mbong, Nathan; Kreso, Antonia; Schoof, Erwin M.; Wagenblast, Elvin; Ng, Stanley W.K.; Krivdova, Gabriela; Jin, Liqing; Nakauchi, Hiromitsu; Dick, John E.

Published in:
Cell Reports

DOI:
10.1016/j.celrep.2018.10.021

Publication date:
2018

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY-NC-ND

Citation for published version (APA):
Integrated Stress Response Activity Marks Stem Cells in Normal Hematopoiesis and Leukemia

Highlights
- ISR pathway activity in human HSC/MPPs is maintained by low eIF2 and high ATF4
- ATF4 upregulation following amino acid deprivation promotes HSC survival
- Functional HSCs can be purified using an ATF4 reporter that measures ISR activity
- ISR activity marks primitive cells in normal and malignant hematopoietic hierarchies

Authors
Peter van Galen, Nathan Mbong, Antonia Kreso, ..., Liqing Jin, Hiromitsu Nakauchi, John E. Dick

Correspondence
john.dick@uhnresearch.ca

In Brief
Hematopoietic stem cells balance apoptosis with survival to maintain lifelong integrity of the blood system. Van Galen et al. show that specific translation dynamics prime normal and leukemia stem cells to activate the integrated stress response, which can enhance survival in the presence of stressors such as amino acid deprivation.

van Galen et al., 2018, Cell Reports 25, 1109–1117
October 30, 2018 © 2018 The Author(s).
https://doi.org/10.1016/j.celrep.2018.10.021
Integrated Stress Response Activity Marks Stem Cells in Normal Hematopoiesis and Leukemia

Peter van Galen,1,9 Nathan Mbong,2,9 Antonia Kreso,3 Erwin M. Schoof,4 Elvin Wagenblast,2 Stanley W.K. Ng,2,5 Gabriela Krivdova,2,6 Liqing Jin,2 Hiromitsu Nakauchi,7,8 and John E. Dick2,6,10,*

1Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA
2Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada
3Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
4The Finsen Laboratory, Rigshospitalet/Biotech Research and Innovation Centre (BRIC), Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark
5Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON M5G 1A1, Canada
6Department of Molecular Genetics, University of Toronto, Toronto, ON MSS 1A8, Canada
7Division of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan
8Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
9These authors contributed equally
10Lead Contact
*Correspondence: john.dick@uhnresearch.ca
https://doi.org/10.1016/j.celrep.2018.10.021

SUMMARY

Lifelong maintenance of the blood system requires equilibrium between clearance of damaged hematopoietic stem cells (HSCs) and long-term survival of the HSC pool. Severe perturbations of cellular homeostasis result in rapid HSC loss to maintain clonal purity. However, normal homeostatic processes can also generate lower-level stress; how HSCs survive these conditions remains unknown. Here we show that the integrated stress response (ISR) is uniquely active in HSCs and facilitates their persistence. Activating transcription factor 4 (ATF4) mediates the ISR and is highly expressed in HSCs due to scarcity of the eIF2 translation initiation complex. Amino acid deprivation results in eIF2α phosphorylation-dependent upregulation of ATF4, promoting HSC survival. Primitive acute myeloid leukemia (AML) cells also display eIF2 scarcity and ISR activity marks leukemia stem cells (LSCs) in primary AML samples. These findings identify a link between the ISR and stem cell survival in the normal and leukemic contexts.

INTRODUCTION

Replenishment of the blood system throughout the lifetime of an organism requires longevity and integrity of the stem cell pool. However, human HSCs are sensitive to perturbations of cellular homeostasis and prone to undergo apoptosis. The induction of reactive oxygen species (ROS) and accumulation of DNA damage leads to heightened apoptosis of HSCs compared to downstream progenitor cells (Milyavsky et al., 2010; Yahata et al., 2011). Likewise, endoplasmic reticulum (ER) stress causes strong activation of the unfolded protein response in HSCs, resulting in increased apoptosis compared to progenitor cells (Mi-harada et al., 2014; van Galen et al., 2014a). These responses promote stem cell pool integrity by purging damaged stem cells, but to ensure longevity, HSCs also must be able to survive perturbations that regularly occur during homeostasis such as DNA damage and calorie restriction (Ho et al., 2017; Warr et al., 2013). The signals that ensure persistence of HSCs in the context of lower-level stress caused by metabolic processes during normal homeostasis are unknown.

Many stressors converge on the ISR pathway. This pathway serves to balance stress signals that activate cell death pathways with those that protect the cell to enable restoration of cellular homeostasis (Pakos-Zebrucka et al., 2016). In low-stress conditions, the ISR favors survival as a consequence of the intrinsic stability of adaptive mRNAs and proteins, whereas high stress levels tip the balance toward distal ISR targets that promote cell death (Han et al., 2013; Rutkowski et al., 2006). This survival-death equilibrium is maintained by four stress-inducible kinases: GCN2, PKR, HRI, and PERK (Figure 1A). These kinases phosphorylate eIF2α, a subunit of the eIF2 complex (consisting of eIF2α, β, and γ), thereby preventing formation of the ternary complex (eIF2, GTP, and Met-tRNA) (Atikken and Lorsch, 2012). This leads to attenuation of global translation initiation, which conserves amino acid pools for essential cellular functions, relieves chaperones of their load, and lowers metabolic demands associated with protein synthesis (Wek et al., 2006). Thus, the ISR integrates many different stressors and initiates global translational attenuation as a protective mechanism.

Highly regulated translation dynamics are critical for HSCs, and recent studies revealed the importance of ribosomal proteins and translation factors to maintain stem cell self-renewal and lineage commitment (Blanco et al., 2016; Cai et al., 2015; Khajuria et al., 2018; Signer et al., 2014, 2016). The ISR delays translation initiation through eIF2α phosphorylation. Paradoxically, ISR-induced eIF2α phosphorylation increases translation of specific transcription factors including activating transcription factor 4 (ATF4), ATF5, and CHOP (DDIT3), with ATF4 being the
most direct ISR effector (Pakos-Zebrucka et al., 2016). Mechanistically, ternary complex scarcity leads to ribosomal bypass of an inhibitory upstream open reading frame (uORF) in the ATF4 mRNA, leading to efficient ATF4 translation and protein upregulation (Lu et al., 2004). Transcriptional targets of ATF4 include regulators of amino acid metabolism, redox balance,
autophagy, and protein synthesis (B’chir et al., 2013; Han et al., 2013; Harding et al., 2003). Thus, ISR activation results in efficient translation of ATF4, which in turn activates gene networks to facilitate restoration of cellular homeostasis.

The ISR regulates cellular homeostasis in various tissues and cancer cells, but it has typically been studied in bulk populations. Whether the ISR plays distinct roles within the individual cells that make up a tissue hierarchy like the hematopoietic system is unknown. By monitoring ATF4 activity in normal and malignant blood cells, we show that the pro-survival ISR pathway is integral to modulating stem cell stress responses.

RESULTS

**High Integrated Stress Response Activity in HSC/MPPs Compared to Progenitors**

To assess the expression levels of key ISR pathway components, we analyzed the proteome of purified human HSCs and progenitor cells. Quantitative label-free mass spectrometry revealed lower protein levels of eIF2α, eIF2β, and eIF2γ in HSC/MPPs (multipotent progenitors) compared to downstream progenitors (Figure 1B; Table S1) (E.M.S., S. Xie, A. Mitchell, K.B. Kaufmann, Y. Ge, E. Lechman, T. Kislinger, B.T. Porse, J.E.D., unpublished data). Analysis of more highly purified HSC and progenitor populations showed that eIF2 subunits are similarly expressed in HSCs, MPPs, and multilymphoid progenitors (MLPs), but upregulated in downstream granulocyte-macrophage progenitors (GMPs) (Figure 1C), which is also seen in mouse hematopoiesis (Klämmek et al., 2012; Signer et al., 2014). To assess levels of total and phosphorylated eIF2α (P-eIF2α), we used immunohistochemistry and intracellular flow cytometry. Within the progenitor compartment, we observed heterogeneity with low and high expression of eIF2α, which may represent different levels within committed progenitor cells of the erythroid, myeloid, and lymphoid lineages. In HSC/MPPs, levels of eIF2α and P-eIF2α were lower on average than in progenitors (Figure 1D; Figures S1A–S1C). The eIF2α kinase PKR was lower in HSC/MPPs compared to progenitors, whereas GCN2 showed an opposite trend (Figure S1D). These data show that key ISR components are distinctly regulated within the hematopoietic hierarchy and that eIF2α, β, and γ protein levels are low in HSC/MPPs.

Low eIF2-GTP-Met-tRNAi ternary complex leads to efficient translation of ATF4, the principal transcription factor that activates ISR target genes. To gain more insight into ATF4 regulation and activity in HSCs and progenitor cells, we used gene expression data from sorted stem and progenitor cell populations from lineage-depleted cord blood (lin– CB) (Laurenti et al., 2013). ATF4 mRNA is highly expressed in CB progenitor cells (mean detection of three ATF4 probes is in the top 20% of 29,331 probes). Furthermore, ATF4 expression is higher in HSC/MPPs compared to progenitors, consistent with previous qPCR results (van Galen et al., 2014a) (Figure 1E). Of the 225 recently identified ATF4 target genes (Han et al., 2013), 54 were differentially expressed between HSC/MPP and myeloid progenitor cells (Figure 1F; STAR Methods). Gene set enrichment analysis showed that this set of 54 ATF4 target genes is significantly enriched in HSC/MPPs compared to progenitor cells (false discovery rate FDR < 0.001; Figure 1G), suggesting that ATF4 is active in HSCs and contributes to the transcriptional activation of ISR target genes.

**ATF4 Reporter Measures ISR Activation**

To monitor ATF4 translation, we utilized a lentiviral ATF4 reporter (ATF4rep) that increases translation of an ATF4-GFP fusion gene under conditions of stress that result in eIF2α phosphorylation (Figure S2A) (van Galen et al., 2014a). To determine the specificity of the ATF4rep to different kinds of stress, we transduced TLS-ERG-immortalized cord blood cells (TX cells) with the ATF4rep and treated them with various stressors. As expected, the ER stress agent thapsigargin, which is commonly used to induce eIF2α phosphorylation, increased ATF4rep 2.1-fold, as measured by the transgene ratio (TGR) between GFP and TagBFP (Figure 2A; STAR Methods). In contrast, bortezomib, which disrupts proteostasis but is not known to function through the ISR, did not cause a notable increase of the ATF4rep TGR. Similarly, the mTOR inhibitor temsirolimus, the translation elongation inhibitor cycloheximide, and the histone deacetylase inhibitor valproic acid did not induce ATF4rep, despite having an impact on cell viability (Figure S2B). Negative and positive control vectors showed no change of the ATF4rep TGR (Figures S2C and S2D). Collectively, these results indicate that the ATF4rep is efficiently induced by ISR activation but not by stressors that are independent of the ISR.

To assess the functionality of the ATF4rep in primary human blood stem and progenitor cells, we transduced lin– CB cells with the ATF4rep and assessed ATF4 protein levels in sorted GFP-high and GFP-low cells (Figure 2B). ATF4 protein levels were higher in GFP-high cells, indicating that GFP provides a measure for the level of endogenous ATF4. We previously showed that severe tunicamycin-induced ER stress activates the ATF4rep in lin– CB cells (van Galen et al., 2014a). Other conditions, such as oxidative stress or amino acid deprivation, may lead to less severe stress in the native environment of HSCs. We subjected ATF4rep-transduced CD34+ CB cells to hypoxia and valine depletion, the latter of which strongly induced ATF4rep activation (Figure 2C). More broadly, depletion of 13 amino acids induced the ATF4rep in lin– CB cells (Figure 2D). Thus, amino acid deprivation strongly induces ISR activation and ATF4 translation in primitive human CB cells.

**ATF4 Upregulation through eIF2α Phosphorylation Promotes CB Cell Survival**

Phosphorylation of eIF2α reduces ternary complex availability and increases ATF4 levels because slow translation reinitiation favors the ATF4 ORF instead of the inhibitory uORF (Figure S2A) (Lu et al., 2004). To investigate whether ATF4rep activation following valine depletion depends on eIF2α phosphorylation, we transduced CD34+ CB cells with overexpression vectors of wild-type eIF2α and eIF2αS52A, a mutant protein that cannot be inactivated by phosphorylation. Following overexpression of wild-type eIF2α, valine depletion resulted in strong ATF4rep activation in CD34+ CB cells (10-fold TGR increase; Figure 2E). In contrast, overexpression of eIF2αS52A abolished valine depletion-induced activation of the ATF4rep, indicating that eIF2α phosphorylation is responsible for ATF4 upregulation following
Figure 2. ISR Activates the ATF4 Reporter and Protects against Valine Depletion
(A) Bar plots show TGR of ATF4transduced TEX cells that were treated with indicated stressors. Data are shown as mean ± SD of n = 2 technical replicates, representative of n = 3 similar experiments.
(B) Western blot shows ATF4 levels in sorted GFP-low and GFP-high ATF4transduced lin− CB cells that were treated with thapsigargin. GAPDH is the loading control. Results are representative of n = 2 CB samples.
(C) Bar plots shows ATF4trans TGR of transduced CD34+ CB cells that were cultured in hypoxic conditions or valine deficient media. Data are shown as mean ± SD of n = 3 time points. Flow cytometry histograms show GFP intensity of TagBFP+ cells at indicated conditions. Letters indicate which amino acid is removed; ‘ indicates hydrochloride.
(D) Bar plot shows ATF4trans TGR of transduced lin− CB cells that were cultured in complete (full) medium or media depleted of individual amino acids. Data are shown as mean ± SD of n = 2 CB samples.
(E) Bar plot shows TGR of ATF4transduced lin− CB cells that were overexpressed or underexpressed eIF2α WT or eIF2αS52A (marked by mOrange). Data are shown as mean ± SD of n = 3 CB samples. Representative histograms show GFP intensity of mOrange+TagBFP+ CB cells.
(F) Bar plot shows TGR of ATF4transduced CD34+ CB cells that were co-transduced with shRNAs for eIF2S1, eIF2S2, or eIF2S3 (marked by mCherry). ATF4trans TGR of mCherry+TagBFP+ cells is shown as mean ± SD for n = 3 CB samples.
(G and H) Bar plots show cell proliferation (G) and apoptosis (H) of CD34+ CB cells that were transduced with shATF4 vectors and cultured without valine. Data are shown as mean ± SD of n = 4 CB samples.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S2.
valine depletion. Knockdown of eIF2α, eIF2β, or eIF2γ increased ATF4rep activity (Figure S2E; Figure 2F), indicating that eIF2 availability regulates ATF4 translation. These data establish that valine depletion leads to eIF2α phosphorylation, which reduces ternary complex availability resulting in efficient ATF4 translation.

ATF4 upregulation can induce an adaptive response to diverse stimuli such as oxidative stress, whereas the same pathway can also improve survival, we transplanted lin− CB cells expressing high ATF4rep activity (Figure S2E; Figure 2F) into mice (Figure S3B). The level of engraftment from GFP-high cells was increased compared to GFP-low cells (Figure 3D). Furthermore, the number of engrafted mice from GFP-high cells was increased compared to GFP-low cells (Figure 3E).

**Human HSC/MPPs Display High ISR Activity under Basal Conditions**

To assess ISR activity across the human hematopoietic hierarchy, we sorted CD34+CD38− HSC/MPPs and CD34+CD38+ progenitors from lin− CB and transduced them with the ATF4rep transgene. After 4 days in culture, ATF4rep TGR was 1.6-fold higher in HSC/MPPs compared to progenitors (Figure 3A; Figure S3A), indicating that HSC/MPPs have high ISR activity compared to committed progenitors. ATF4rep TGR further declined in downstream common myeloid progenitor and megakaryocyte-erythroid progenitor (CMP and MEP) populations and, compared to HSC/MPPs, HSCs display higher ISR activity than progenitors when assessed in basal conditions, which may contribute to HSC endurance.

To determine if the high ISR activity in HSCs is associated with improved survival, we transplanted lin− CB cells expressing high ATF4rep activity (GFP-high) and low ATF4rep activity (GFP-low) into mice (Figure S3B). The level of engraftment from GFP-high cells was increased compared to GFP-low cells (Figure 3D). Furthermore, the number of engrafted mice from GFP-high cells

---

**Figure 3. Human HSC/MPPs Display High ISR Activity under Basal Conditions**

(A) Bar plot shows ATF4rep TGR of CB cells, 4 days after sorting and transduction. TagBFP-only cells were transduced with a vector lacking the ATF4-GFP transgene. Data are shown as mean ± SEM of n = 4 CB samples. Representative histogram shows GFP intensity of TagBFP cells. (B and C) Scatter column plots show ATF4rep TGR in CB cell populations, isolated from engrafted mice. (B) Each symbol represents the BM of one mouse. Data are shown as mean ± SD. (C) Each symbol represents one BM pool, combined from several mice, for n = 3 CB samples. The p values indicate comparisons to HSC/MPP fractions. Error bars indicate mean ± SD. (D) Scatter column plots show engraftment of lin− CB cells that were transduced, sorted based on ATF4rep TGR, and injected into mice. Every symbol represents 30,000 cells. (E) Limiting dilution analysis shows the frequency of engrafting cells in bulk, GFP-low, and GFP-high lin− CB cell populations. Pooled data from n = 4 CB samples are normalized to CD33+ cells. (F) ATF4rep activity (Figure S2E; Figure 2F), indicating that eIF2 availability regulates ATF4 translation. These data establish that valine depletion leads to eIF2α phosphorylation, which reduces ternary complex availability resulting in efficient ATF4 translation. After 4 days in culture, ATF4rep TGR was 1.6-fold higher in HSC/MPPs compared to progenitors (Figure 3A; Figure S3A), indicating that HSC/MPPs have high ISR activity compared to committed progenitors. ATF4rep TGR further declined in downstream common myeloid progenitor and megakaryocyte-erythroid progenitor (CMP and MEP) populations and, compared to HSC/MPPs, HSCs display higher ISR activity than progenitors when assessed in basal conditions, which may contribute to HSC endurance.

To determine if the high ISR activity in HSCs is associated with improved survival, we transplanted lin− CB cells expressing high ATF4rep activity (GFP-high) and low ATF4rep activity (GFP-low) into mice (Figure S3B). The level of engraftment from GFP-high cells was increased compared to GFP-low cells (Figure 3D). Furthermore, the number of engrafted mice from GFP-high cells
cells in the GFP-low population; bulk TagBFP+ cells possessed was 1 in 19,804 cells in the GFP-high population and 1 in 71,922 tion analysis, we calculated that the frequency of engrafting cells was increased compared to GFP-low cells. Using limiting dilu-
tion analysis, we calculated that the frequency of engrafting cells was 1 in 19,804 cells in the GFP-high population and 1 in 71,922

Enrichment of Human LSCs Based on High ISR Levels

The hierarchical structure of normal hematopoiesis is partially maintained in acute myeloid leukemia (AML) and leukemia stem cells (LSCs) that share numerous stemness properties with normal HSCs are responsible for disease propagation (Dick, 2008). We examined the expression of central ISR components in AML cell populations. Similar to our findings in normal CB cells, mass spectrometry revealed lower

[A] Heatmaps show protein detection by label-free mass spectrometry in sorted CD34+CD38− and CD34+CD38+ cells from 11 AML patients. Some fractions are not tested because we could not obtain a sufficient number of cells to perform mass spectrometry. Colors indicate normalized protein quantities (log2, and centered).

[B] Gene set enrichment analysis shows ATF4 targets (from Figure 1F) in a gene list ranked by the fold difference between sorted CD34+CD38− and CD34+CD38+ AML cells. mRNA expression in AML fractions was previously assessed by RNA sequencing (RNA-seq) (Ng et al., 2016).

[C] Flow histogram shows GFP intensity of primitive (CD34+) and differentiated (CD34−) ATF4REP-transduced TagBFP+ 8227 cells. Results are representative of n = 2 independent experiments.

[D] Line graph shows population doublings of sorted 8227 cells. Viable cells were counted at 6-day intervals. Data are shown as mean ± SD of n = 3 technical replicates.

[E] Graphic overview of experiment to assess ATF4REP TGR in AML CD34/CD38 populations, and secondary transplantation to assess LSC potential of GFP-low and GFP-high AML cells.

(F) Line graph shows ATF4REP TGR in phenotypic fractions of human AML samples that were isolated from engrafted mice. Each symbol represents mean ± SD of ≥ 5 mice; results were normalized to the maximum TGR of that experiment.

(G) Dot plots show secondary engraftment levels of AML cells that were recovered from primary mice, sorted based on ATF4REP TGR, and retransplanted. Every dot represents median secondary engraftment (normalized to the average) of one AML sample.

*p < 0.05, ****p < 0.0001. See also Figures S3 and S4.
8227 AML cells and assessed culture-initiating capacity, a surrogate assay for LSC function. Only GFP-high cells were able to expand in culture for over 3 weeks (Figure 4D), indicating that ATF4<sup>rep</sup> activity can be used to prospectively isolate cells that display features of primitive LSCs.

We wanted to evaluate ATF4<sup>rep</sup> expression in the malignant hierarchy using primary AML patient samples. Since <i>in vitro</i> expansion of primary AML cells is challenging and does not maintain the developmental hierarchy, we transduced AML cells with the ATF4<sup>rep</sup> and established AML in immunodeficient mice (Figure 4E; Table S2). After 6–8 weeks, mice were sacrificed and human AML cells were assessed for CD34/CD38 expression and ATF4<sup>rep</sup> TGR by flow cytometry. In four out of five samples, the ATF4<sup>rep</sup> TGR was higher in CD34<sup>+</sup> compared to CD34<sup>−</sup> cells (Figure 4F; Figure S4A). AML09191 was an exception, showing higher ATF4<sup>rep</sup> TGR in CD34<sup>−</sup> compared to CD34<sup>+</sup> cells. Taken together, these ATF4<sup>rep</sup> measurements suggest that most primary AML samples have high ISR activity in phenotypically primitive cells.

Although CD34 can enrich for LSCs in most AML cases, the surface phenotype of AML cells can be decoupled from LSC activity. To test whether primary AML cells that possess high ISR activity are enriched for LSC function, we sorted TagBFP<sup>+</sup> (bulk), GFP-low and GFP-high populations and transplanted cells into secondary recipient mice (Figure 4E). GFP-high cells showed higher engraftment in three out of eight samples, with two additional samples showing the same trend (Figure S4B). In AML09191, GFP-high cells showed higher engraftment, indicating that ATF4<sup>rep</sup> activity maintained its correlation with LSC activity despite its negative correlation with CD34 expression. On average, GFP-high cells showed 8.5-fold higher secondary engraftment than GFP-low cells (p < 0.0001; Figure 4G). These data indicate that high ISR activity is associated with normal and malignant stem cells.

**DISCUSSION**

Our data establish that the ISR-mediated pro-survival program is uniquely wired in HSCs where it plays a role in governing HSC function. The tendency of HSCs to undergo apoptosis following stress and damage (Milyavsky et al., 2010; van Galen et al., 2014a; Yahata et al., 2011) needs to be balanced with alleviation of low-level perturbations that occur under homeostasis to ensure HSC functionality. Our results show that amino acid deprivation is one such perturbation where ATF4-dependent pro-survival signals play a protective role. We show that high expression of the ISR effector ATF4 is contingent on eIF2 scarcity, representing a mechanism of ISR activity that may also safeguard stem cells in other tissues (Blanco et al., 2016; Zismanov et al., 2016). ATF4 is modulated by additional signals including mTOR and post-translational modifications (Ben-Sahra et al., 2016; Wortel et al., 2017). Several processes that are important for HSC maintenance are regulated by ATF4, including autophagy, amino acid metabolism and oxidative stress resistance (B’chir et al., 2013; Harding et al., 2003; Ho et al., 2017; Taya et al., 2016). Accordingly, ATF4-mediated reduction of oxidative stress has been implicated to maintain erythropoiesis and HSC development in mice (Suragani et al., 2012; Zhao et al., 2015). Additional studies are required to elucidate the full complement of signals upstream and downstream of ATF4 in different conditions. In cancer, ATF4 has been shown to confer resistance to nutrient deprivation, hypoxia, and ROS (Rouschop et al., 2013; Ye et al., 2010). Considering the protective role of ATF4 for HSCs undergoing valine depletion, AML therapies that affect amino acid metabolism should take into account ATF4-dependent adaptive mechanisms (Heydt et al., 2018; Jacque et al., 2015; Miraki-Moud et al., 2015; Willems et al., 2013). The conservation of ISR signaling in primitive CB and a subset of primary AML samples supports the possibility of targeting LSCs through the ISR pathway and underscores the importance of monitoring adaptive responses in developmentally distinct cancer cell subpopulations. Further evaluation of eIF2α phosphorylation and its upstream kinases in activation of the ISR and how this is differentially regulated in HSC and specific progenitor subsets may inform strategies to modulate this pathway and stem cell fate outcomes. Understanding the interplay between stemness, translational control, and stress signaling is needed to manipulate stem cells for therapeutic purposes, such as promoting HSC survival during transplantation and gene therapy or targeting the survival of LSCs.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **CONTACT FOR REAGENT AND RESOURCE SHARING**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Cord blood (CB) and acute myeloid leukemia (AML) samples
  - CB, TEX, and 8227 cell preparation and liquid culture
  - Mouse xenotransplantation
- **METHOD DETAILS**
  - Lentiviral vectors
  - shRNA knock-down constructs
  - Quantitative PCR
  - Amino acid depletion
  - Thapsigargin, cycloheximide, valproic acid, temsirolimus, and bortezomib
  - Mass spectrometry
  - Fluorescence-Activated Cell Sorting (FACS) and intracellular flow cytometry
  - Apoptosis and cell proliferation assays
  - Immunofluorescence
  - Western blot
  - Transcriptional analysis
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
- **DATA AND SOFTWARE AVAILABILITY**

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes four figures and three tables can be found with this article online at https://doi.org/10.1016/j.celrep.2018.10.021.
ACKNOWLEDGMENTS

We thank David Ron, Brad Wouters, Adam Wilkinson, Elisa Laurenti, and all Dick lab members for critical advice; the obstetrics units of Trillium Health Partners (Mississauga and Credit Valley sites) for CB units; and the SickKids-UHN flow facility staff for technical support. P.v.G. is a Leukemia and Lymphoma Society Fellow (S458-17). E.M.S. is supported by the European Molecular Biology Organization (ALTF 1595–2014), the European Commission (LIFTOFUND2013, GA–2013–609409), and Marie Curie Actions. E.W. is supported by the Human Frontier Science Program. The work in J.E.D.’s lab is funded by the Canadian Institutes for Health Research, Canadian Cancer Society Research Institute, Terry Fox Foundation, Genome Canada through the Ontario Genomics Institute, Ontario Institute for Cancer Research, a Canada Research Chair, the Princess Margaret Hospital Foundation, and the Ontario Ministry of Health and Long Term Care (OMOHLTC). The views expressed in this manuscript do not necessarily reflect those of the OMOHLTC.

AUTHOR CONTRIBUTIONS


DECLARATION OF INTERESTS

J.E.D. has sponsored research agreements with Celgene and is on the Scientific Advisory Board of Trillium Therapeutics.

Received: April 5, 2018
Revised: July 25, 2018
Accepted: October 2, 2018
Published: October 30, 2018

REFERENCES


## STAR★METHODS

### KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibodies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alexa Fluor 488 Goat anti-Rabbit IgG</td>
<td>ThermoFisher Scientific</td>
<td>Cat# A-11034; RRID: AB_2578217</td>
</tr>
<tr>
<td>Mouse monoclonal eiF2a (D3)</td>
<td>Santa Cruz Biotech</td>
<td>Cat# sc-133132</td>
</tr>
<tr>
<td>Phospho-eIF2a (Ser52)</td>
<td>ThermoFisher Scientific</td>
<td>Cat# 701268; RRID: AB_2532450</td>
</tr>
<tr>
<td>Rabbit monoclonal phospho-eIF2a (Ser51)</td>
<td>ThermoFisher Scientific</td>
<td>Cat# 44-728G; RRID: AB_10983400</td>
</tr>
<tr>
<td>ATF4-4 (D4B8) Rabbit monoclonal</td>
<td>Cell Signaling</td>
<td>Cat# 11815; RRID: AB_2616025</td>
</tr>
<tr>
<td>Rabbit monoclonal GAPDH (14C10)</td>
<td>Cell Signaling</td>
<td>Cat# 2118; RRID: AB_581053</td>
</tr>
<tr>
<td>PE-Cy7 Mouse Anti-Human CD38 (HB7)</td>
<td>BD</td>
<td>Cat# 335790</td>
</tr>
<tr>
<td>APC-Cy7 Mouse Anti-Human CD34</td>
<td>BD PharMingen</td>
<td>Cat# 624072</td>
</tr>
<tr>
<td>APC Mouse Anti-Human CD45 (2D1)</td>
<td>BD</td>
<td>Cat# 340943</td>
</tr>
<tr>
<td>PE Mouse Anti-Human CD33 (P67.6)</td>
<td>BD</td>
<td>Cat# 347787</td>
</tr>
<tr>
<td>V450 Mouse Anti-Human CD7 (M-T701)</td>
<td>BD</td>
<td>Cat# 642916</td>
</tr>
<tr>
<td>PE Mouse Anti-Human CD19 (SJ25C1)</td>
<td>BD</td>
<td>Cat# 340364</td>
</tr>
<tr>
<td>PE-Cy5 Mouse Anti-Human CD90</td>
<td>BD PharMingen</td>
<td>Cat# 555597</td>
</tr>
<tr>
<td>PE-Cy5 Mouse Anti-Human CD10</td>
<td>Beckman Coulter</td>
<td>Cat# PN IM2721U</td>
</tr>
<tr>
<td>Biotin Mouse Anti-Human CD45RA</td>
<td>BD PharMingen</td>
<td>Cat# 555487</td>
</tr>
<tr>
<td>PE Mouse Anti-Human CD135 (FLT3)</td>
<td>BD PharMingen</td>
<td>Cat# 558996</td>
</tr>
<tr>
<td>PE-Cy5 Mouse Anti-Human CD49f</td>
<td>BD PharMingen</td>
<td>Cat# 551129</td>
</tr>
<tr>
<td>Biotin Mouse Anti-Human CD135</td>
<td>BD PharMingen</td>
<td>Cat# 624008</td>
</tr>
<tr>
<td><strong>Bacterial and Virus Strains</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vesicular Stomatitis virus G protein (VSVG)</td>
<td>Addgene</td>
<td>Plasmid# 14888</td>
</tr>
<tr>
<td>pMDLg/pRRE plasmid</td>
<td>Addgene</td>
<td>Plasmid# 60488</td>
</tr>
<tr>
<td>pRSV-Rev</td>
<td>Addgene</td>
<td>Plasmid# 12253</td>
</tr>
<tr>
<td><strong>Biological Samples</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary AML Patient Samples</td>
<td>Princess Margaret Cancer Center</td>
<td></td>
</tr>
<tr>
<td>Healthy Human Umbilical Cord Blood Donor</td>
<td>Trillium Health Partners</td>
<td></td>
</tr>
<tr>
<td>Healthy Human Umbilical Cord Blood Donor</td>
<td>Credit Valley Hospital</td>
<td></td>
</tr>
<tr>
<td><strong>Chemicals, Peptides, and Recombinant Proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stem Cell Factor (SCF)</td>
<td>Miltenyi Biotec</td>
<td>Cat# 130-096-696</td>
</tr>
<tr>
<td>Fms-related tyrosine kinase ligand (FLT3-L)</td>
<td>Miltenyi Biotec</td>
<td>Cat# 130-096-474</td>
</tr>
<tr>
<td>Human Thrombopoietin (TPO)</td>
<td>Miltenyi Biotec</td>
<td>Cat# 130-095-752</td>
</tr>
<tr>
<td>Human Interleukin-6 (IL-6)</td>
<td>Miltenyi Biotec</td>
<td>Cat# 130-093-934</td>
</tr>
<tr>
<td>Human Granulocyte-Colony stimulating factor (G-CSF)</td>
<td>Miltenyi Biotec</td>
<td>Cat# 130-094-265</td>
</tr>
<tr>
<td>X-Vivo Chemically Defined Serum</td>
<td>Lonza</td>
<td>Cat# 04-380Q</td>
</tr>
<tr>
<td>Human Interleukin-3 (IL-3)</td>
<td>Miltenyi Biotec</td>
<td>Cat# 130-095-068</td>
</tr>
<tr>
<td>Iscove’s Modified Dulbecco’s Medium (IMDM)</td>
<td>GIBCO</td>
<td>Cat# 1240053</td>
</tr>
<tr>
<td>RIPA Buffer</td>
<td>Thermo Fisher</td>
<td>Cat# 899000</td>
</tr>
<tr>
<td>BCA Protein Assay Kit</td>
<td>ThermoFisher Scientific</td>
<td>Cat# 23225</td>
</tr>
<tr>
<td>Thapsigargin</td>
<td>Sigma-Aldrich</td>
<td>Cat# T9033</td>
</tr>
<tr>
<td>Cycloheximide</td>
<td>Sigma-Aldrich</td>
<td>Cat# C7698</td>
</tr>
<tr>
<td>Valproic Acid</td>
<td>Sigma-Aldrich</td>
<td>Cat# PHR1061</td>
</tr>
</tbody>
</table>

(Continued on next page)
**CONTACT FOR REAGENT AND RESOURCE SHARING**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, John E. Dick (John.Dick@uhnresearch.ca).

**EXPERIMENTAL MODEL AND SUBJECT DETAILS**

**Cord blood (CB) and acute myeloid leukemia (AML) samples**

All human samples were obtained with informed consent according to procedures approved by the Institutional Review Boards of the University Health Network, Trillium Hospital, and/or Credit Valley Hospital. Mononuclear cells were obtained by centrifugation of CB on Ficoll (Ficoll-Paque Premium GE Healthcare) followed by red blood cell lysis with ammonium chloride solution (StemCell

---

### Critical Commercial Assays

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bortezomib</td>
<td>Cell Signaling</td>
<td>Cat# 2204</td>
</tr>
<tr>
<td>Temsirolimus</td>
<td>Sigma-Aldrich</td>
<td>Cat# P20020</td>
</tr>
<tr>
<td>Anti-EIF2S1(phospho-S51)</td>
<td>Abcam</td>
<td>Cat# Ab32157; RRID: AB_732117</td>
</tr>
</tbody>
</table>

---

### Experimental Models: Cell Lines

<table>
<thead>
<tr>
<th>EXPERIMENTAL MODELS: CELL LINES</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEX cells</td>
</tr>
<tr>
<td>8227 cells</td>
</tr>
<tr>
<td>MOLM13</td>
</tr>
</tbody>
</table>

### Experimental Models: Organisms/Strains

<table>
<thead>
<tr>
<th>EXPERIMENTAL MODELS: ORGANISMS/STRAINS</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOD/Lt-scid/IL2Rγnull (NSG)</td>
</tr>
</tbody>
</table>

### Oligonucleotides

See Table S3 for oligonucleotide sequences.

### Recombinant DNA

<table>
<thead>
<tr>
<th>RECOMBINANT DNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATF4^{AP}</td>
</tr>
<tr>
<td>ATF4,12^{AP}</td>
</tr>
<tr>
<td>ATF4,14^{AP}</td>
</tr>
<tr>
<td>eIF2α^{WT-OE}</td>
</tr>
<tr>
<td>eIF2α^{S52A-OE}</td>
</tr>
<tr>
<td>pLBC2</td>
</tr>
</tbody>
</table>

### Software and Algorithms

<table>
<thead>
<tr>
<th>SOFTWARE AND ALGORITHMS</th>
</tr>
</thead>
<tbody>
<tr>
<td>FACSDiva</td>
</tr>
<tr>
<td>FlowJo10</td>
</tr>
<tr>
<td>Prism 7.0a</td>
</tr>
<tr>
<td>RStudio Version 1.1.456 using R 3.5.1</td>
</tr>
</tbody>
</table>
Technologies). Lineage depletion of mononuclear cells was achieved using StemSep Human Progenitor Cell Enrichment Kit according to the manufacturer’s protocol (StemCell Technologies). Thawed Lin- CB cells were transduced as described previously (van Galen et al., 2014b). Freshly thawed primary AML samples harvested from patients’ peripheral blood were exposed to lentivirus for 19 hours. Details of AML patient samples are outlined in Table S2.

**CB, TEX, and 8227 cell preparation and liquid culture**

Lineage depleted CB cells were stored in IMDM with 50% FCS and 10% DMSO at CB, TEX, and 8227 cell preparation and liquid culture according to the manufacturer’s protocol (StemCell Technologies). Thawed Lin- CB cells were transduced as described previously (van Ga-...len et al., 2014b). Freshly thawed primary AML samples harvested from patients’ peripheral blood were exposed to lentivirus for 19 hours. Details of AML patient samples are outlined in Table S2.

**Mouse xenotransplantation**

Animal work was carried out in accordance with guidelines approved by the University Health Network Animal Care Committee. 8-11 week-old male NOD/Lt-scid/IL2Rnull (NSG) mice were sublethally irradiated (225 cGy using a 137Cs γ-iradiator) 24h prior to intrafemoral transplantation. CB cells were transduced, expanded in vitro for up to 4 days and injected into the right femur with 30 µl PBS (Figures 3B and 3C) or sorted into TagBFP+ (bulk), TagBFP*GFP-low and TagBFP*GFP-high populations and injected at 10,000 or 30,000 cells per mouse (Figures 3D and 3E). Mice were euthanized after 8-11 weeks and the femurs were flushed with PBS with 2% FCS. Cells were stained for surface markers and analyzed for TagBFP*CD45* engraftment. Human engraftment was scored as positive if the mouse BM had > 1% CD45*TagBFP* cells. Primary AML samples were transduced overnight and transplanted at 100,000 or 300,000 cells per mouse into the right femur with 30 µl PBS. After eight weeks, primary mice were sacrificed and their BM was analyzed by flow cytometry. To evaluate functional LSC content, pooled BM cells were sorted and transplanted into secondary recipient mice at multiple cell doses. After 11 weeks, BM cells were analyzed by flow cytometry.

**METHOD DETAILS**

**Lentiviral vectors**

The ATF4 reporter was used as previously reported (van Galen et al., 2014a). Briefly, the plasmids ATF4.5: 5’ATF4.GFP (Addgene 21852), ATF4.12: 5’ATF4.uORF1&2AUA.GFP (Addgene 21859), and ATF4.14: 5’ATF4.uORF1&2AUA.GFP (Addgene 21861) were used to construct the bidirectional lentiviral reporter vectors ATF4rep, the negative control ATF4.12rep, and the positive control ATF4.14rep. These three vectors are identical apart from uORF start codon mutations. For the “TagBFP only” control, luciferase was cloned downstream of the SFFV promoter. We used the transgene ratio between GFP and TagBFP to account for differences in basal translation (TGR = GFP mean fluorescence intensity / TagBFP mean fluorescence intensity) as a measure of reporter activity. To generate elf2αS52A- OE, we mutated codon 52 from Serine to Alanine in EiF2S1 plasmid (Harvard plasmid clone HsCD00044214). Using Q5 Site-Directed mutagenesis kit (NEB E0554S) with mutagenic primers TAGTGAATTAGCCAGAAGGCG and AGAAGAATCATGCCTTCAAATG, the desired mutated elf2αS52A was amplified and cloned downstream of the bidirectional minhCMV-SFFV promoter using the Gateway compatible pLBC-OM-RFCA vector that also expresses mOrange.

**shRNA knock-down constructs**

shRNA sequences were predicted based on the Sherwood algorithm (Knott et al., 2014). shRNA oligo’s were ordered as Ultramers from IDT and PCR amplified using AmpliTaq Gold 360 Polymerase (ThermoFisher) with shRNA amplification primers (Table S3). The PCR product was subsequently digested with BamH1 and Mlu1 and cloned into the pLBC2 vector downstream of mCherry.

**Quantitative PCR**

Total RNA from cells was purified and DNase treated using the RNeasy Micro Kit (QIAGEN). RNA integrity was measured on the Agilent Bioanalyzer (RNA nano kit, RNA integrity scores were > 9). cDNA was synthesized using SuperScript VILO cDNA Synthesis Kit (ThermoFisher). Quantitative PCR analysis was performed on the LightCycler 480 Instrument II (Roche). All signals were quantified with PBS with 2% FCS. Cells were stained for surface markers and analyzed for TagBFP*CD45* engraftment. Human engraftment was scored as positive if the mouse BM had > 1% CD45*TagBFP* cells. Primary AML samples were transduced overnight and transplanted at 100,000 or 300,000 cells per mouse into the right femur with 30 µl PBS. After eight weeks, primary mice were sacrificed and their BM was analyzed by flow cytometry. To evaluate functional LSC content, pooled BM cells were sorted and transplanted into secondary recipient mice at multiple cell doses. After 11 weeks, BM cells were analyzed by flow cytometry.

**Amino acid depletion**

AA depleted media were provided by Dr. Hiromitsu Nakauchi (Stanford University). CB cells were transduced with the ATF4 reporter. After 24hrs, cells were washed and plated in various AA depleted conditions supplemented with 1% BSA, 100 U/ml penicillin-streptomycin, and cytokines: SCF (50ng/ml), G-CSF (5ng/ml), Flt3L (50ng/ml), TPO (7.5ng/ml) and IL-6 (5ng/ml). TLS-ERG-immortalized CB (TEX) cells were expanded in X-VIVO 10 (BioWhittaker) supplemented with 1% BSA, 2 mM L-Glutamine, 100 U/ml penicillin-streptomycin, and cytokines: SCF (50ng/ml), G-CSF (5ng/ml), FLT3L (50ng/ml), TPO (7.5ng/ml) and IL-6 (5ng/ml). 8227 cell preparation and liquid culture in IMDM with 15% FBS, 200mM L-glutamine, SCF (100ng/ml), IL-3 (10ng/ml) (Warner et al., 2005). The AML cell line 8227 was cultured in X-Vivo media supplemented with cytokines as described (Lechman et al., 2016).

**Quantitative PCR**

Total RNA from cells was purified and DNase treated using the RNeasy Micro Kit (QIAGEN). RNA integrity was measured on the Agilent Bioanalyzer (RNA nano kit, RNA integrity scores were > 9). cDNA was synthesized using SuperScript VILO cDNA Synthesis Kit (ThermoFisher). Quantitative PCR analysis was performed on the LightCycler 480 Instrument II (Roche). All signals were quantified with PBS with 2% FCS. Cells were stained for surface markers and analyzed for TagBFP*CD45* engraftment. Human engraftment was scored as positive if the mouse BM had > 1% CD45*TagBFP* cells. Primary AML samples were transduced overnight and transplanted at 100,000 or 300,000 cells per mouse into the right femur with 30 µl PBS. After eight weeks, primary mice were sacrificed and their BM was analyzed by flow cytometry. To evaluate functional LSC content, pooled BM cells were sorted and transplanted into secondary recipient mice at multiple cell doses. After 11 weeks, BM cells were analyzed by flow cytometry.

**Thapsigargin, cycloheximide, valproic acid, temsirolimus, and bortezomib**

Compounds were purchased as follows: thapsigargin, Sigma-Aldrich, catalog number T9033; cycloheximide, Sigma-Aldrich, catalog number C7698; valproic acid Sigma-Aldrich, P8401; temsirolimus, P8401; bortezomib, Cell Signaling catalog number 2204; temsirolimus, and bortezomib. Compounds were purchased as follows: thapsigargin, Sigma-Aldrich, catalog number T9033; cycloheximide, Sigma-Aldrich, catalog number C7698; valproic acid Sigma-Aldrich, P8401; temsirolimus, P8401; bortezomib, Cell Signaling catalog number 2204; temsirolimus, and bortezomib.
Sigma-Aldrich, catalog number PZ0020. All compounds were resuspended in DMSO and stored at −20°C until use. Final DMSO concentration was ≤1% in both control and treatments groups. Cell counts and viability analysis were carried out after 30 h of drug treatment and thapsigargin was used at 0.2 μM.

**Mass spectrometry**

CB cells were thawed through dropwise addition of 50% FBS, 50% X-vivo 10 and 1% DNase, washed, and stained for 30 minutes on ice either 1) with CD34 APC-Cy7 and CD38 PE-Cy7 at a 1:100 dilution to sort HSC/MPP versus progenitor cells, or 2) with CD45RA BB515, CD90 PE, CD10 APC, CD7 V450 at 1:50, and CD34 APC-Cy7 and CD38 PE-Cy7 at 1:200 dilution to sort HSC, MPP, MLP and GMP (Table S1). Equal amounts of sorted cells (100,000 for low-resolution sorts, 50,000 for high-resolution sorts) were processed for mass spectrometry analysis as described (Lechman et al., 2016). Label-free quantitation was used to derive protein intensities and resulting data was analyzed using MaxQuant (Cox et al., 2014; Cox and Mann, 2008). Protein quantities are shown in heatmaps of log2 detection values. Values were centered by subtracting row means.

**Fluorescence-Activated Cell Sorting (FACS) and intracellular flow cytometry**

Immunophenotyping for human hematopoietic cell surface markers was carried out using the following antibodies: APC-conjugated anti-CD45 (1:100 2D1), PE-conjugated anti-CD33 (1:100 P67.6) V450-conjugated anti-CD7 (1:50 M-T701), PE-Cy7-conjugated anti-CD38 (1:100 HB7), APC-Cy7-conjugated anti-CD34, Biotin-conjugated anti-CD135 (1:50), PE-Cy5-conjugated anti-CD49f (1:100), PE-conjugated anti-CD33 (1:100 P67.6). V450-conjugated anti-CD7 (1:50 M-T701), PE-Cy7-conjugated anti-CD45RA (1:50), PE-Cy5 conjugated anti-CD90 (1:100). CB cells were stained with antibodies for 30 min at 4°C. FACS sorting was performed using FACSAria sorters, and FlowJo software was used for data analysis.

For intracellular flow cytometry, CB cells were fixed with 80% methanol for 5 min, permeabilized with 0.1% PBS-Tween-20 for 30 min and incubated in PBS with 10% goat serum and 0.3M glycine. Cells were stained with primary antibody (total eIF2α: Santa Cruz sc-133132, Phospho-eIF2α: Abcam 32157) for 30 min at room temperature and washed three times with PBS buffer by centrifugation at 300 g for 5 min each time. Secondary antibody (Alexa Fluor 488, Thermo Fisher Scientific A11034) was added to the cells at 1:500 dilution for 30 min and incubated in PBS with 10% goat serum and 0.3M glycine. Cells were then fixed and permeabilized, and EdU incorporation into newly synthesized DNA was detected using Pacific Blue Click-it Plus EdU azide (ThermoFisher Scientific #C10636).

**Apoptosis and cell proliferation assays**

For the apoptosis assay, CB cells were washed with PBS and diluted in 1X Annexin V binding buffer to 1 × 10^6 in 0.5ml. Cells were stained in Annexin V-FITC at room temperature in the dark for 15 minutes. For the proliferation assay, CB cells were incubated at 37°C with 10μM of EdU for one hour. Cells were then fixed and permeabilized, and EdU incorporation into newly synthesized DNA was detected using Pacific Blue Click-it Plus EdU azide (ThermoFisher Scientific #C10636).

**Immunofluorescence**

CB cells were sorted based on CD34, CD38, and CD45RA. Cells were cytospun and fixed with 4% formaldehyde. Cells were then blocked with 1X PBS with 5% normal serum and 0.3% Triton X-100 for 1h and stained with primary antibody for 1h (total eIF2α: Santa Cruz sc-133132, Phospho-eIF2α: Thermo Fisher Scientific 701268). Fluorochrome-conjugated secondary antibodies (Alexa Fluor-488 and Alexa Fluor-555) were applied for 1h. Coverslips were applied to slides with Prolong® Gold Antifade Reagent with DAPI. Images were obtained using an Olympus FluoView 1000 Laser Scanning Confocal Microscope and analyzed using Olympus Fluoview 1.1. Fluorochrome-specific signal intensity was quantified and normalized to cell areas selected from n = 8 images per stain.

**Western blot**

CD34+ CB cells were treated with 0.2 μM thapsigargin for 30 hours. GFP-low and GFP-high fractions were sorted and 50,000 cells were lysed with RIPA buffer (Thermo Fisher Scientific 899000) containing protease and phosphatase inhibitors (Thermo Fisher Scientific 78446). Samples were centrifuged at 12,000 g for 5 min at 4°C and supernatants were used in western assay. Protein concentration was measured by BCA protein assay (Thermo Fisher Scientific 23225). Western size assay was performed with ProteinSimple Wes separation instrument. Samples were prepared and resolved on the 12-230 kDa capillary cartridge according to manufacturer’s instructions. Antibodies (Cell Signaling anti-ATF4 #11815 and anti-GAPDH #2118) were titrated on a lysate from CD34+ CB cells prior to the experiment to determine the optimal dilutions, which was 1:5 for ATF4 and 1:200 for GAPDH (capillary western uses very concentrated samples requiring higher antibody concentrations than regular western blot). Note that we used a monoclonal C-terminal antibody that does not overlap with the ATF4-GFP fusion gene in the ATF4ΔCt vector (Cell Signaling #11815).

**Transcriptional analysis**

Expression levels of ATF4 and ATF4 target genes were assessed in CB microarray datasets that were previously reported (Laurenti et al., 2013). To display ATF4 expression, the log2 values of three probes were corrected (by adding 1.87, −2.43 and 0.56) to equalize each HSC1 value to the mean HSC1 value across the three probes (Figure 1E). To determine expression of ATF4 targets in CB progenitors, we started from a list of target genes that was previously defined by ER stress induction in mouse embryo fibroblasts followed by ATF4 and CHOP ChIP-seq and RNA-seq (Han et al., 2013). Considering our specific interest in ATF4, we only assessed 254 ATF4-specific target genes (Overlap: ATF4 ONLY), and not CHOP (103) or common (218) targets. Gene symbol conversion using...
BioMart identified 225 human homologs. Of these 225 genes, we found that 54 were differentially expressed in HSC/MPPs (HSC1, HSC2 and MPP) compared to myeloid progenitors (CMP, GMP, and MEP, p < 0.01 by Student’s t test) in previously reported microarrays (Laurenti et al., 2013). These 54 genes are shown in a heatmap (log2, and centered expression values) and used for GSEA (Figures 1F, 1G, and 4B).

**QUANTIFICATION AND STATISTICAL ANALYSIS**

Statistical details are provided in the figure legends. Unless otherwise noted, mean ± standard deviation values are given and *P* values are calculated by two-tailed unpaired Student’s t test using Microsoft Excel (version 16.17). To compare engraftment levels, we performed Mann–Whitney U-tests, as these data do not show a normal distribution, using Prism software (version 7.0a; GraphPad). To analyze *in vivo* limiting dilution analysis, we used ELDA software (Hu and Smyth, 2009) (http://bioinf.wehi.edu.au/software/elda). For heatmaps of mRNA and protein expression, expression values from microarrays or MaxQuant were log2 transformed, centered, and visualized using the image function and a blue to white to red color gradient using R statistical software (RStudio Version 1.1.456). Stars are used to indicate significance in the figures: *p* < 0.05, **p** < 0.01, ***p*** < 0.001, ****p*** < 0.0001.

**DATA AND SOFTWARE AVAILABILITY**

The accession number for previously reported microarrays of CB progenitors is GEO: GSE42414 (Laurenti et al., 2013). The accession number for previously reported RNA-seq of AML fraction is GEO: GSE76009 (Ng et al., 2016). Mass spectrometry analysis of hematopoietic progenitor cells is in preparation for publication (E.M.S., S. Xie, A. Mitchell, K.B. Kaufmann, Y. Ge, E. Lechman, T. Kilsinger, B.T. Porse, J.E.D., unpublished data).